Tuesday, November 22, 2016

UPDATE 1-AstraZeneca cleared to resume enrolment in cancer drug trials

* Trials involve AstraZeneca's immunotherapy durvalumab

(Adds shares, further details on immunotherapy)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)